Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results
StockNews.AI • 406 days
High Materiality8/10
Information
TUCSON, Ariz. , Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerat...
Original sourceAI Summary
AXDX anticipates FDA submission for WAVE system after clinical trial enrollment completion. Preliminary 2024 revenue at $11.7 million, down from $12.1 million year-over-year. Company reported reduced cash burn and sustained 350 Pheno instruments in operation. Anticipates launch of WAVE system in late 2025 with vast Gram-Negative testing capabilities. Achieved 510(k) clearance for Accelerate Arc system enhancing rapid microbial identification.
Sentiment Rationale
With anticipated product launches and FDA approval, AXDX's prospects appear promising compared to past performances.
Trading Thesis
The upcoming product launches and clinical results may steadily enhance investor sentiment over time.
Market-Moving
- AXDX anticipates FDA submission for WAVE system after clinical trial enrollment completion.
- Preliminary 2024 revenue at $11.7 million, down from $12.1 million year-over-year.
- Company reported reduced cash burn and sustained 350 Pheno instruments in operation.
Key Facts
- AXDX anticipates FDA submission for WAVE system after clinical trial enrollment completion.
- Preliminary 2024 revenue at $11.7 million, down from $12.1 million year-over-year.
- Company reported reduced cash burn and sustained 350 Pheno instruments in operation.
- Anticipates launch of WAVE system in late 2025 with vast Gram-Negative testing capabilities.
- Achieved 510(k) clearance for Accelerate Arc system enhancing rapid microbial identification.
Companies Mentioned
- PHNO (PHNO)
Corporate Developments
The advancements in clinical trials and upcoming FDA approvals are crucial for AXDX's growth.